Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02100657 | Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 | 39 | PharmaMarINDUSTRY | 2 | Oct 12, 2020 | clinicaltrials |
| NCT01248923 | A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 55 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 30, 2020 |
| NCT00469209 | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01570387 | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Boston Medical CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01842308 | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01593696 | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | completed | Phase 1 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2020 | clinicaltrials |
| NCT02343536 | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | completed | Phase 1 | 59 | CelgeneINDUSTRY | 1 | Aug 28, 2020 | clinicaltrials |
| NCT01561833 | A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients | completed | Phase 1 | 12 | Yale UniversityOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01403948 | BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
| NCT01542918 | Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma | completed | Phase 1 | 14 | James RubensteinOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT02064387 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 | completed | Phase 1 | 79 | GlaxoSmithKlineINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
| NCT01921387 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT02211014 | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma | completed | Phase 1 | 27 | Acerta Pharma BVINDUSTRY | 2 | Jul 31, 2020 | clinicaltrials |
| NCT01866839 | Preventing Stem Cell Transplant Complications With a Blood Separator Machine | completed | Phase 1 / Phase 2 | 41 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 21, 2020 | clinicaltrials |
| NCT03042793 | Vaccination With PD-L1 Peptide Against Multiple Myeloma | completed | Phase 1 | 10 | Lene Meldgaard KnudsenOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02055820 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | completed | Phase 1 / Phase 2 | 267 | Hoffmann-La RocheINDUSTRY | 10 | Jun 11, 2020 | clinicaltrials |
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma(ALCI) | completed | Phase 1 | 74 | Baylor College of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03027284 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT00729118 | Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01916135 | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT01212952 | Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT01155817 | Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease | completed | Phase 1 | 33 | Stanford UniversityOTHER | 2 | Apr 15, 2020 | clinicaltrials |
| NCT02912676 | Thiopurine EnhAnced Maintenance Therapy(TEAM) | completed | Phase 1 / Phase 2 | 30 | Kjeld SchmiegelowOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT02492750 | Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | completed | Phase 1 | 14 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03483688 | A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects | completed | Phase 1 | 6 | Peking Union Medical College HospitalOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00854139 | Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD) | completed | Phase 1 | 10 | Massachusetts General HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT01491841 | IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma(BRP) | completed | Phase 1 | 33 | Anne Beaven, MDOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT00918723 | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02603445 | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 24, 2020 | clinicaltrials |
| NCT01691898 | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(ROMULUS) | completed | Phase 1 / Phase 2 | 231 | Genentech, Inc.INDUSTRY | 6 | Feb 21, 2020 | clinicaltrials |
| NCT01049945 | Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 70 | Mayo ClinicOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01447056 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases(MALTED) | completed | Phase 1 | 37 | Baylor College of MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03068351 | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | completed | Phase 1 | 24 | Hoffmann-La RocheINDUSTRY | 3 | Feb 7, 2020 | clinicaltrials |
| NCT00003954 | Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 2 | Feb 6, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01464112 | A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 18 | Janssen Research & Development, LLCINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 12, 2020source: clinicaltrials